Measuring Clinical Benefit in Neonatal Randomized Clinical Trials: Challenges and Opportunities

Many of the therapeutics commonly used in neonatal intensive care units (NICU) are not specifically labeled or approved for use in neonates (ie, defined as infants less than 28 days of life, or less than 28 days corrected age for preterm infants).a As such, clinicians lack critical safety and efficacy information on the use of medical products to treat neonatal conditions. Additionally, neonatal-specific medical conditions frequently lack safe and effective treatments, resulting in an unmet need for drug development.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Workshop/Symposium Summary Source Type: research